Infection à pneumocoque

Thèmes

Guidance, tools, and resources for evidence-based decisions on vaccine switches and EPI portfolio optimization

Organisé par: Molly Sauer

Voir tous les Thèmes

Du Centre de Connaissances

Pneumococcal conjugate vaccine cost calculator for middle-income countries

UNICEF Pricing Information-PCV

Considerations for PCV product choice

VIEW-hub data on PCV introductions, coverage, and products

Auteur: Anand Anbarasu, Paul Livingstone, Sudha Ramaiah, Reetika Debroy, Gayathri Ashok, Soumya Basu

PCV catch-up vaccination FAQ

Auteur: Iqbal Hossain, Daniel Ali, Ibrahim Dadari, Niklas Danielsson, Rachel V. Belt, Samir V. Sodha, Ananya Iyengar, Arindam Ray

P7 Optimizing vaccine regimens

Auteur: Kirsten Ward

VIEW-hub by IVAC

Auteur: UNICEF, World Health Organization (WHO)

WHO position papers

P2.2 Lessons from Rotavirus and Pneumococcal Conjugate Vaccines

Auteur: World Health Organization (WHO)

W3.3 The Future of Pneumococcal Conjugate Vaccines

Auteur: Rebecca Alban, Tafwirapo Chihana, Chifuniro Chiyendausiku

Considerations for Pneumococcal Conjugate Vaccine (PCV) Product Choice

Auteur: The ROTA Council

COSTVAC tool

Auteur: World Health Organization (WHO)

Vaccine-Preventable Diseases (including pipeline vaccines)

UNIVAC

Auteur: Noni MacDonald, Dalhousie U.

Vaccine Impact Modelling Consortium (VIMC)

Auteur: Lee Hall

Calculateur du coût des vaccins pneumococcique conjugués

Auteur: World Health Organization (WHO)

W3.2 Rollout of Pneumococcal Conjugate Vaccine in India

Auteur: World Health Organization (WHO)

W3.1 2018 Status of Pneumococcal Conjugate Vaccine Use and Impact

W3 Pneumococcal Vaccines: Lessons Learned and the Road Ahead

Auteur: Laura Nic Lochlainn

Global Market Study: Pneumococcal Conjugate (PCV) and Polysaccharide (PPV) vaccines - June 2020

Auteur: Barney Graham

Pneumococcal Conjugate Vaccine Cost Calculator

Auteur: Charlie Weller

Pneumococcal Vaccine: Handling the change in product manufacturer and presentation

Auteur: Peter Dull, Sinead Delany-Moretlwe

Pneumococcal Conjugate Vaccine (PCV) 4-dose vial presentations - Frequently Asked Questions (FAQs)

Auteur: Abdul Momin Kazi

Characteristics of different presentations of Pneumococcal Conjugate Vaccines

Auteur: Alejandro Cravioto, Shahida Baqar

Towards the introduction of pneumococcal conjugate vaccines in Bhutan: A cost-utility analysis to determine the optimal policy option

Auteur: Philippe-Alexandre Gilbert

2017 Pneumonia and Diarrhea Progress Report: Driving Progress through Equitable Investment and Action

Auteur: Raman Rao, Jessica Martinez

Incidence of invasive pneumococcal disease before and during an era of use of three different pneumococcal conjugate vaccines in Quebec

Auteur: Melanie Saville

Pneumonia & Diarrhea Progress Report, 2017

Auteur: Annie Mo, Jerome Kim

Prevnar-13 vaccine failure in a mouse model for vitamin A deficiency

Auteur: Martin Friede

Immunogenicity of 13-valent pneumococcal conjugate vaccine among children with underlying medical conditions

Auteur: Max Silverman, Sue Ann Clemens

What is the heterogeneity in the impact seen with pneumococcal conjugate vaccines telling us?

Auteur: Ruth Karron, Carolyn Deal

PCV Evidence Base

Auteur: World Health Organization (WHO)

PCV Technical Briefings

Auteur: Mathias Garny

Gap Analyses of PCV Vaccine Impact Evaluations in Settings of Routine Use

Auteur: Melkamu Ayalew

Long-term impact of a "3 + 0" schedule for 7- and 13-valent pneumococcal conjugate vaccines on invasive pneumococcal disease in Australia, 2002-2014

Auteur: VillageReach

When free is not fair: the case of vaccine donations

Auteur: VillageReach

An eHealth Project on Invasive Pneumococcal Disease: Comprehensive Evaluation of a Promotional Campaign.

Auteur: VillageReach

Effect of Tdap when administered before, with or after the 13-valent pneumococcal conjugate vaccine (coadministered with the quadrivalent meningococcal conjugate vaccine) in adults: A randomised controlled trial

Auteur: VillageReach

Long-term antibody persistence study (3 years after last dose) of the 7-valent pneumococcal conjugate vaccine in young children in China

Auteur: VillageReach

Impact of pneumococcal conjugate vaccine in children morbidity and mortality in Peru: Time series analyses

Auteur: VillageReach

Indoor air pollution and delayed measles vaccination increase the risk of severe pneumonia in children: Results from a case-control study in Mwanza, Tanzania

Auteur: Chang-Yuil Kang

Health gains and financial protection from pneumococcal vaccination and pneumonia treatment in Ethiopia: Results from an extended cost-effectiveness analysis

Auteur: Timothy Chege

Impact of the introduction of the pneumococcal conjugate vaccine in the Brazilian routine childhood national immunization program

Auteur: Josphat Kiprop Kosgei

Impact of routine PCV7 (Prevenar) vaccination of infants on the clinical and economic burden of pneumococcal disease in Malaysia

Auteur: Chul Kim

Geographic Information System and tools of spatial analysis in a pneumococcal vaccine trial

Auteur: Dal-Hee Min

A cost-effectiveness analysis of a 10-valent pneumococcal conjugate vaccine in children in six Latin American countries

Auteur: Mohammad Mamun Alam

Improving capture of vaccine history: Case study from an evaluation of 10-valent pneumococcal conjugate vaccine introduction in Kenya

Auteur: Debasu Damtie

Changes in childhood pneumonia hospitalizations by race and sex associated with pneumococcal conjugate vaccines

Auteur: Hitt Sharma

Pneumonia’s second wind? A case study of the global health network for childhood pneumonia

Auteur: Peter Dull

Successful introduction of an underutilized elderly pneumococcal vaccine in a national immunization program by integrating the pre-existing public health infrastructure

Auteur: Michelo Simuyandi

Tracking financial flows for immunization in Honduras

Auteur: Ruth Karron

Vaccine effectiveness of PCV13 in a 3 + 1 vaccination schedule

Auteur: Annelies Wilder-Smith

GAVI study – outsourcing the distribution component of vaccine and medicine supply chains

Auteur: Jessica Fleming

Progress in introduction of pneumococcal conjugate vaccine — worldwide, 2000–2012

Auteur: Cathy Ndiaye

Immunogenicity of 13-valent pneumococcal conjugate vaccine administered according to 4 different primary immunization schedules in infants

Auteur: Halidou Tinto

Serotype-specific changes in invasive pneumococcal disease after pneumococcal conjugate vaccine introduction: A pooled analysis of multiple surveillance sites

Auteur: Alexander Rowe

13-Valent pneumo vaccine (PCV13) in children partially immunized with 7-valent pneumo vaccine

Auteur: Hani Kim

Development and preliminary data on the use of a mobile app specifically designed to increase community awareness of invasive pneumococcal disease and its prevention.

Auteur: Alice Chen

Acute exercise enhancement of pneumococcal vaccination response

Auteur: Peter Andersen

Sentinel versus population-based surveillance of pneumococcal conjugate vaccine effectiveness

Auteur: Darin Edwards

Effects of community-wide vaccination with PCV-7 on pneumococcal nasopharyngeal carriage in Gambia

Auteur: Chunlin Xin

Early impact of 10-valent pneumococcal conjugate vaccine in childhood pneumonia hospitalizations using primary data from an active population-based surveillance

Auteur: Michael Egan

Optimizing the use of pneumococcal conjugate vaccine globally

Auteur: Peter Openshaw

Invasive pneumococcal disease after implementation of 13-valent conjugate vaccine

Auteur: Melanie Saville

Impact of the pneumococcal conjugate vaccines on invasive pneumococcal disease in France, 2001–2012

Auteur: Melanie Saville

Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study

Auteur: Nathalie Garcon

Prevention of pneumococcal infection with vaccines

Auteur: Marta Tufet

The effect of various types of patients' reminders on the uptake of pneumococcal vaccine in adults: A randomized controlled trial

Auteur: Mahima Datla

Pneumococci in the African meningitis belt: meningitis incidence and carriage prevalence in children

Auteur: Patrick Tippoo

Increased paediatric hospitalizations for empyema in Australia after introduction of the 7-valent pneumococcal conjugate vaccine

Auteur: Jerry Sadoff

Determination of pneumococcal serotypes in meningitis cases in Niger, 2003–2011

Auteur: Harry Kleanthous

A research study on the impact of pneumococcal vaccine in Kenya shows data-mining electronic medical records is vital to transforming health care

Auteur: Tarun Saluja

Lives Saved Tool (LiST)

Auteur: Mindy Miner

The impact of heptavalent PCV on the incidence of childhood community-acquired pneumonia & bacteriologically confirmed pneumococcal pneumonia in Japan

Auteur: Anna Seale

Impact of the 13-valent pneumococcal conjugate vaccine on the incidence of pneumococcal meningitis in children

Auteur: Arnaud Didierlaurent

Invasive pneumococcal disease following the introduction of 13-valent conjugate vaccine in children in New York city from 2007 to 2012

Auteur: Rudzani Muloiwa

Immunization in Practice Module 7: Monitoring and using your data

Auteur: Deborah Watson-Jones

Page 1/16

Parcourir le Centre de Connaissances

Du blog

GNN monthly update: May 24'

Dimanche 2 Juin 2024 - par Louise Henaff

Messages de forum récents

Updated Vaccine-Preventable Diseases (VPD) Surveillance Standards Released

Lundi 10 Septembre 2018 - par Minal Patel

New blog: "Getting to 'Mars' with immunization delivery"

Mardi 13 Octobre 2015 - par Laura Kallen

IVAC VIMS Report on Global Vaccine Introduction - September 2015 Now Available!

Lundi 21 Septembre 2015 - par Thuy-Linh Nguyen

PCV introduction in Cameroon, Ethiopia, Kenya and Mali had marginal impact on EPI and little to none on broader health systems.

Jeudi 17 Septembre 2015 - par Patrick Lydon

The International Symposium on Pneumococci and Pneumococcal Diseases, 2014: Presentations

Jeudi 6 Novembre 2014 - par Moderator

Post00342 : GAVI UPDATE

Mardi 15 Mai 2001 - par Moderator

Post00336 : GAVI INFORMATION UPDATE

Mardi 24 Avril 2001 - par Moderator

Post00331 : GAVI INFORMATION UPDATE

Mardi 27 Mars 2001 - par Moderator

Post00328 : GAVI UPDATE

Vendredi 2 Mars 2001 - par Moderator

Post00328 : GAVI UPDATE

Vendredi 2 Mars 2001 - par Moderator

Post00328 : GAVI UPDATE

Vendredi 2 Mars 2001 - par Moderator

POST 00262b : VACCINES & IMMUNIZATION NEWS

Jeudi 29 Juin 2000 - par Moderator

Page 1/3

Parcourir le Forum

Membres de Technet-21

Vous devez être connecté pour voir les autres membres.

Événements à venir

Aucun événement à venir.

Offres d'emploi

Aucune offre d'emploi trouvée.

Maladies

Infection à pneumocoque

Thèmes

Du Centre de Connaissances

Du blog

Messages de forum récents

Membres de Technet-21

Événements à venir

Offres d'emploi

À propos

Centre de connaissances

Communauté

Plus